SI3784666T1 - Antiproliferacijske spojine in njihove uporabe - Google Patents
Antiproliferacijske spojine in njihove uporabeInfo
- Publication number
- SI3784666T1 SI3784666T1 SI201930251T SI201930251T SI3784666T1 SI 3784666 T1 SI3784666 T1 SI 3784666T1 SI 201930251 T SI201930251 T SI 201930251T SI 201930251 T SI201930251 T SI 201930251T SI 3784666 T1 SI3784666 T1 SI 3784666T1
- Authority
- SI
- Slovenia
- Prior art keywords
- antiproliferation
- compounds
- antiproliferation compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862661719P | 2018-04-24 | 2018-04-24 | |
| EP19726792.5A EP3784666B1 (en) | 2018-04-24 | 2019-04-23 | Antiproliferation compounds and uses thereof |
| PCT/US2019/028607 WO2019209759A1 (en) | 2018-04-24 | 2019-04-23 | Antiproliferation compounds and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI3784666T1 true SI3784666T1 (sl) | 2022-07-29 |
Family
ID=66655429
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201930251T SI3784666T1 (sl) | 2018-04-24 | 2019-04-23 | Antiproliferacijske spojine in njihove uporabe |
Country Status (26)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL301501B2 (en) | 2018-04-24 | 2024-10-01 | Vertex Pharma | Antiproliferation compounds and uses thereof |
| WO2020010451A1 (en) * | 2018-07-10 | 2020-01-16 | Trillium Therapeutics Inc. | Heteroaromatic-fused imidazolyl amides, compositions and uses thereof as sting agonists |
| WO2020236834A1 (en) * | 2019-05-20 | 2020-11-26 | Seshadri Raju | Modified z stents for iliac vein stenting |
| CN115103840B (zh) | 2019-12-20 | 2025-07-22 | 拜耳公司 | 取代的噻吩甲酰胺、噻吩甲酸及其衍生物 |
| US20240132464A1 (en) * | 2022-09-28 | 2024-04-25 | Accutar Biotechnology Inc. | Heterocyclic compounds as e3 ligase inhibitors |
| WO2025223536A1 (zh) * | 2024-04-26 | 2025-10-30 | 正大天晴药业集团股份有限公司 | 稠合双环化合物及其用途 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
| DE19840028A1 (de) | 1998-09-02 | 2000-03-09 | Max Planck Gesellschaft | Nucleinsäuremoleküle codierend Enzyme, die Fructosyltransferaseaktivität besitzen, und deren Verwendung |
| OA12118A (en) | 1999-12-10 | 2006-05-04 | Pfizer Prod Inc | PyrroloÄ2,3-dÜpyrimidine compounds. |
| PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| KR100833371B1 (ko) | 2001-04-27 | 2008-05-28 | 젠야쿠코교가부시키가이샤 | 헤테로시클릭 화합물 및 이를 유효 성분으로 하는 항종양제 |
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| MXPA05001766A (es) | 2002-08-14 | 2005-08-19 | Atugen Ag | Uso de proteina quinasa n beta. |
| WO2004089925A1 (en) | 2003-04-03 | 2004-10-21 | Semafore Pharmaceuticals, Inc. | Pi-3 kinase inhibitor prodrugs |
| ES2382377T3 (es) | 2003-05-30 | 2012-06-07 | Gemin X Pharmaceuticals Canada Inc. | Compuestos triheterocíclicos, composiciones, y métodos para tratar cáncer |
| WO2005007623A2 (en) | 2003-07-03 | 2005-01-27 | The Trustees Of The University Of Pennsylvania | Inhibition of syk kinase expression |
| LT2612862T (lt) | 2004-05-13 | 2017-01-25 | Icos Corporation | Chinazolinonai kaip žmogaus fosfatidilinozitol-3-kinazės delta inhibitoriai |
| US7449458B2 (en) | 2005-01-19 | 2008-11-11 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
| ES2493466T3 (es) | 2005-05-12 | 2014-09-11 | Abbvie Bahamas Ltd. | Promotores de la apoptosis |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| US7402325B2 (en) | 2005-07-28 | 2008-07-22 | Phoenix Biotechnology, Inc. | Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander |
| HRP20140975T1 (hr) | 2005-10-07 | 2014-11-21 | Exelixis, Inc. | Derivati n-(3-amino-hinoksalin-2-il)-sulfonamida i njihova uporaba kao inhibitora fosfatidilinozitol 3-kinaze |
| WO2007053452A1 (en) | 2005-11-01 | 2007-05-10 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
| HUE028588T2 (hu) | 2005-12-13 | 2016-12-28 | Incyte Holdings Corp | Heteroaril-szubsztituált pirrolo[2,3-b]piridinek és pirrolo[2,3-b]pirimidinek mint Janus-kináz inhibitorok |
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| KR101533461B1 (ko) | 2006-04-26 | 2015-07-02 | 에프. 호프만-라 로슈 아게 | Pi3k저해제로 유용한 티에노[3,2-d]피리미딘 유도체 |
| EP2529621B1 (en) | 2006-09-22 | 2016-10-05 | Pharmacyclics LLC | Inhibitors of bruton's tyrosine kinase |
| PE20081229A1 (es) | 2006-12-01 | 2008-08-28 | Merck & Co Inc | Antagonistas de receptor de orexina de diazepam sustituido |
| HUE029188T2 (en) | 2007-03-12 | 2017-03-28 | Ym Biosciences Australia Pty | Phenylamino-pyrimidine compounds and their use |
| US8394794B2 (en) | 2007-03-23 | 2013-03-12 | Regents Of The University Of Minnesota | Therapeutic compounds |
| PE20090717A1 (es) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
| MY165582A (en) | 2008-03-11 | 2018-04-05 | Incyte Holdings Corp | Azetidine and cyclobutane derivatives as jak inhibitors |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| DE102008031517A1 (de) | 2008-07-03 | 2010-01-07 | Merck Patent Gmbh | Pyrrolopyridinyl-pyrimidin-2-yl-amin-derivate |
| US8163763B2 (en) | 2008-07-31 | 2012-04-24 | Genentech, Inc. | Pyrimidine compounds, compositions and methods of use |
| AR076014A1 (es) | 2009-04-02 | 2011-05-11 | Sanofi Aventis | Derivados de 3- (1,4) oxazepan -4-pirimidona |
| CN102753528A (zh) * | 2009-12-04 | 2012-10-24 | 霍夫曼-拉罗奇有限公司 | 作为单胺重摄取抑制剂的二苯基氮杂*衍生物 |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| EP3256132A1 (en) | 2015-02-13 | 2017-12-20 | Merck Patent GmbH | Pyrimidine derivatives for use in the treatment of cancer |
| IL301501B2 (en) | 2018-04-24 | 2024-10-01 | Vertex Pharma | Antiproliferation compounds and uses thereof |
-
2019
- 2019-04-23 IL IL301501A patent/IL301501B2/en unknown
- 2019-04-23 LT LTEPPCT/US2019/028607T patent/LT3784666T/lt unknown
- 2019-04-23 TW TW108114146A patent/TWI813673B/zh active
- 2019-04-23 KR KR1020207033873A patent/KR102813581B1/ko active Active
- 2019-04-23 FI FIEP22161962.0T patent/FI4043460T3/fi active
- 2019-04-23 SG SG11202009500QA patent/SG11202009500QA/en unknown
- 2019-04-23 IL IL278142A patent/IL278142B2/en unknown
- 2019-04-23 SI SI201930251T patent/SI3784666T1/sl unknown
- 2019-04-23 ES ES22161962T patent/ES2987356T3/es active Active
- 2019-04-23 DK DK19726792.5T patent/DK3784666T3/da active
- 2019-04-23 HU HUE19726792A patent/HUE058746T2/hu unknown
- 2019-04-23 SM SM20220308T patent/SMT202200308T1/it unknown
- 2019-04-23 ES ES19726792T patent/ES2919572T3/es active Active
- 2019-04-23 JP JP2020559394A patent/JP7304892B2/ja active Active
- 2019-04-23 WO PCT/US2019/028607 patent/WO2019209759A1/en not_active Ceased
- 2019-04-23 MX MX2020011089A patent/MX2020011089A/es unknown
- 2019-04-23 CN CN201980036896.XA patent/CN112236428B/zh active Active
- 2019-04-23 US US16/391,419 patent/US10815225B2/en active Active
- 2019-04-23 HR HRP20241163TT patent/HRP20241163T1/hr unknown
- 2019-04-23 PL PL19726792.5T patent/PL3784666T3/pl unknown
- 2019-04-23 EP EP19726792.5A patent/EP3784666B1/en active Active
- 2019-04-23 HR HRP20220710TT patent/HRP20220710T1/hr unknown
- 2019-04-23 CA CA3098335A patent/CA3098335A1/en active Pending
- 2019-04-23 DK DK22161962.0T patent/DK4043460T3/da active
- 2019-04-23 RS RS20220537A patent/RS63281B1/sr unknown
- 2019-04-23 PL PL22161962.0T patent/PL4043460T3/pl unknown
- 2019-04-23 PT PT221619620T patent/PT4043460T/pt unknown
- 2019-04-23 EP EP22161962.0A patent/EP4043460B1/en active Active
- 2019-04-23 PT PT197267925T patent/PT3784666T/pt unknown
- 2019-04-23 HU HUE22161962A patent/HUE067936T2/hu unknown
- 2019-04-23 AU AU2019261308A patent/AU2019261308B2/en active Active
- 2019-04-23 AR ARP190101062A patent/AR114496A1/es active IP Right Grant
-
2020
- 2020-08-27 US US17/004,109 patent/US11440907B1/en active Active
- 2020-09-30 ZA ZA2020/06071A patent/ZA202006071B/en unknown
-
2022
- 2022-06-10 CY CY20221100409T patent/CY1125433T1/el unknown
- 2022-09-07 US US17/930,352 patent/US12195453B2/en active Active
-
2023
- 2023-06-05 JP JP2023092450A patent/JP2023101824A/ja active Pending
-
2024
- 2024-11-08 US US18/941,447 patent/US20250188070A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL285177A (en) | compounds and their use | |
| IL273236A (en) | Pyrazolopyrimidine compounds and their uses | |
| IL277502A (en) | Compounds and uses for them | |
| IL286497A (en) | compounds and their use | |
| IL294052B2 (en) | Fluoroalkyl oxadiazoles and their uses | |
| SG11202100071YA (en) | Fusosome compositions and uses thereof | |
| GB201803568D0 (en) | Novel compounds and uses | |
| IL278142A (en) | Antiproliferative compounds and their uses | |
| IL276753A (en) | Epibrotic compounds, their devices and uses | |
| IL272055A (en) | 8,1-naphthyridinone compounds and their uses | |
| IL291499A (en) | Azaquinoline compounds and their uses | |
| ZA202105752B (en) | Haloallylamine compounds and application thereof | |
| GB201801102D0 (en) | New compounds and uses | |
| IL284764A (en) | compounds and their uses | |
| IL279483A (en) | Cyanotriazole compounds and their uses | |
| IL287503A (en) | Thio-semicarbazide compounds and their use | |
| IL280644A (en) | Magnesium-serinate compound and use thereof | |
| GB201816553D0 (en) | Novel compounds and therapeutic uses thereof | |
| GB201812078D0 (en) | Novel compounds and their uses | |
| GB201806349D0 (en) | New compounds and uses | |
| ZA202201239B (en) | Aminothiolester compounds and uses thereof | |
| GB201804098D0 (en) | Novel compounds and therapeutic uses thereof | |
| IL280369A (en) | Myokines and their uses | |
| IL283540A (en) | Dock1 inhibitory compound and use thereof | |
| GB201810667D0 (en) | New compounds and uses |